SEARCH RESULTS FOR:

Tyrone Brewer

PRESIDENT, US ONCOLOGY, JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
"I am excited about Janssen’s aspirational vision to eliminate cancer. With targeted therapies and immunotherapies, cancer treatment can be more effective and less toxic, enabling individuals to manage their disease while also maintaining their quality of life."

Joe Panetta

PRESIDENT AND CEO, BIOCOM CALIFORNIA
"The lifecycle of new product introduction into the market will now be shorter, as companies have fewer years to recover revenue as a result of the IRA."

Alan Driscoll

VP, DIRECTOR OF MINING SERVICES, FORSGREN ASSOCIATES
"The changing regulatory environment, pressure to streamline the permitting process, and significant investment coming into the state are all driving real-time planning, creative strategies, and good organization."

Joseph Kemp

VICE PRESIDENT AND GENERAL MANAGER - BALD MOUNTAIN, KINROSS GOLD CORPORATION
"Interestingly, despite increasingly challenging operating environments, the industry’s ounce production continues to maintain or improve. That speaks to the creativeness and technical expertise of the whole value chain of the industry."

Andrea Confetti & Roberto Fanelli

EXCLUSIVE SYNTHESIS BUSINESS UNIT LEADER (AC) & CATALOGUE APIS BU DEPUTY MANAGER (RF), DIPHARMA FRANCIS
RF: "Our experience in developing proprietary chemical processes and alternative solutions to support the generic API industry has been instrumental in rapidly expanding our CDMO activities."

United States Life Sciences 2023 - Digital Interactive

In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.

Peru Mining 2023 Pre-Release II

This second pre-release edition of GBR's PERUMIN 2023 Official Investment Guide comprises an analysis based on more than 70 interviews with the leading executives from the entire mining value chain of the Peruvian mining industry to provide a holistic view of the events taking place in the country, how those events have impacted their activities, and what they expect for the upcoming months.

Daniel Palmacci

PRESIDENT, CELL & GENE DIVISION, LONZA
"We want to give patients the best access to the amazing technology and treatments being developed by cell and gene therapy innovators. This is the modality with the greatest potential in the healthcare industry today."

John Patrick Oroho

PRESIDENT AND GENERAL MANAGER, PORZIO LIFE SCIENCES
"We are always looking at new regulations in the US and worldwide: laws very seldom change incrementally, so we adapt our systems to reflect that."

Eugenio Manzano

EXECUTIVE DIRECTOR, POCHTECA
"We believe that the successful chemical distributor of the future needs to be truly digital and Pochteca is investing heavily to be at the forefront of this trend."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

Latam North and Caribbean Mining 2025 - Digital Interactive

A convergence of high-commodity prices and low valuations, on the back of a structural deficit in exploration and discoveries, has set the perfect scene for increased M&A. The leverage is particularly high for acquisitions in Latam North and the Caribbean, where stocks do not command the high premiums of tier-one jurisdictions. But M&A is only a quick fix to the global resource replenishment crisis. 

PARTNER EVENTS